Clinical study of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma

SHI Guang-long; XU Xue-dong; HUANG Rui; CHAI Na

doi:10.11659/jjssx.05E023051

您当前的位置：

首页 >

文章列表页 >

Clinical study of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma

Clinical Research | 更新时间：2024-01-22

- Clinical study of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma
- JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY Vol. 33, Issue 1, Pages: 43-46(2024)
- 作者机构：
  
  空军军医大学第一附属医院放射诊断科，陕西西安710016
- 作者简介：
- 基金信息：
- DOI：10.11659/jjssx.05E023051
  CLC： R735.7
- Published：25 January 2024，
  
  Received：11 May 2023，
扫描看全文
史广龙,徐学东,黄瑞等.调强放射治疗联合卡瑞利珠单抗治疗中晚期肝细胞肝癌的临床研究[J].局解手术学杂志,2024,33(01):43-46.

SHI Guang-long,XU Xue-dong,HUANG Rui,et al.Clinical study of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(01):43-46.
史广龙,徐学东,黄瑞等.调强放射治疗联合卡瑞利珠单抗治疗中晚期肝细胞肝癌的临床研究[J].局解手术学杂志,2024,33(01):43-46. DOI： 10.11659/jjssx.05E023051.

SHI Guang-long,XU Xue-dong,HUANG Rui,et al.Clinical study of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(01):43-46. DOI： 10.11659/jjssx.05E023051.

摘要

目的

探讨调强放射治疗联合卡瑞利珠单抗对中晚期肝细胞肝癌（HCC）的疗效及安全性。

方法

选取2020年1月至12月我院收治的84例中晚期HCC患者作为研究对象，随机分为观察组和对照组，每组42例。观察组患者采用调强放射治疗联合卡瑞利珠单抗治疗，对照组患者采用调强放射治疗。比较2组患者的近期疗效、免疫功能及远期生存率，记录不良反应发生情况。

结果

观察组患者治疗后1、3个月的总有效率显著高于对照组(

0.05）。与治疗前比较，治疗后1、3个月，2组患者的CD

、CD

/CD

均升高，CD

均下降（

0.05），且观察组CD

、CD

/CD

高于对照组，CD

低于对照组（

0.05）。观察组患者中位生存时间显著长于对照组(

0.05）。观察组患者皮肤毛细血管增生症发生率高于对照组（

0.001），2组患者其他不良反应发生率比较差异无统计学意义（

0.05），且均为1~2级不良反应。

结论

调强放射治疗联合卡瑞利珠单抗对中晚期HCC的疗效较好，可提高机体免疫功能，控制病情发展，且安全性良好。

Abstract

Objective

To investigate the efficacy and safety of intensity-modulated radiation therapy combined with camrelizumab in the treatment of advanced hepatocellular carcinoma （HCC）.

Methods

A total of 84 patients with advanced HCC admitted to our hospital from January to December 2020 were selected as the study objects， and were randomly divided into the observation group and the control group，with 42 cases in each group.Patients in the observation group received intensity-modulated radiation therapy combined with carrellizumab， and patients in the control group received intensity-modulated radiation therapy. The short-term efficacy，immune function and long-term survival rate of patietns in the two groups were compared， and the incidence of adverse reactions was recorded.

Results

The total effective rates of the observation group 1 month and 3 months after treatment were significantly higher than those of the control group （

0.05）. The levels of CD

，CD

and CD

/CD

1 month and 3 months after treatment were all increased in the two groups， while the levels of CD

in both two groups were decreased （

0.05），and the levels of CD

，CD

and CD

/CD

in the observation group were higher than those in the control group （

0.05），and the levels of CD

in the observation group were lower than those in the control group（

0.05）. The median survival time of patients in the observation group was significantly longer than that of patients in the control group （

0.05）. The incidence of cutaneous capillary hyperplasia in the observation group was higher than that in the control group （

0.001），and there was no significant difference in the incidence of other adverse reactions between the two groups （

0.05），and all of adverse reactions were grades 1 to 2.

Conclusion

Intensity-modulated radiation therapy combined with camrelizumab has a good effect on HCC， it can improve the immune function of the body，and control the development of the disease，with good safety.

关键词

调强放射治疗卡瑞利珠单抗中晚期肝细胞肝癌临床疗效安全性

Keywords

intensity-modulated radiation therapycamrelizumabadvancedhepatocellular carcinomaclinical efficacysafety

references

Sung H，Ferlay J，Siegel RL，et al. Global cancer statistics 2020： GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries［J］. CA Cancer J Clin，2021，71（3）： 209-249. doi：10.3322/caac.21660http://dx.doi.org/10.3322/caac.21660.

董旭，潘耀振. 原发性肝癌血管生成及靶向药物治疗研究进展［J］. 世界最新医学信息文摘（连续型电子期刊），2020，20（36）：112-113. doi：10.3969/j.issn.1671-3141.2020.36.047http://dx.doi.org/10.3969/j.issn.1671-3141.2020.36.047.

Kulik L，El-Serag HB. Epidemiology and management of hepatocellular carcinoma［J］. Gastroenterology，2018，156（2）： 477-491.doi：10.1053/j.gastro.2018.08.065http://dx.doi.org/10.1053/j.gastro.2018.08.065.

陆阳，姜永能，万程，等.阿帕替尼联合TACE治疗中晚期肝细胞癌的疗效研究［J］. 介入放射学杂志，2019，28（2）： 162-165.doi：10.3969/j.issn.1008-794X.2019.02.014http://dx.doi.org/10.3969/j.issn.1008-794X.2019.02.014.

Bhangoo RS，Mullikin TC，Ashman JB，et al. Intensity modulated proton therapy for hepatocellular carcinoma： initial clinical experience［J］.Adv Radiat Oncol，2021，6（4）：1-8.doi：10.1016/j.adro. 2021.100675http://dx.doi.org/10.1016/j.adro.2021.100675.

Chen Z，Lu X，Koral K. The clinical application of camrelizumab on advanced hepatocellular carcinoma［J］.Expert Rev Gastroenterol Hepatol，2020，14（11）：1017-1024.doi：10.1080/17474124.2020. 1807939http://dx.doi.org/10.1080/17474124.2020.1807939.

中华人民共和国卫生和计划生育委员会医政医管局.原发性肝癌诊疗规范（2017年版）［J］.中华肝脏病杂志，2017，25（12）：886-895.doi：10.3760/cma.j.issn.1673-9752.2017.07.001http://dx.doi.org/10.3760/cma.j.issn.1673-9752.2017.07.001.

刘燕，石远凯.临床肿瘤内科手册［M］.第5版.北京：人民卫生出版社，2007：152-153.

国家食品药品监督管理局，药品安全监管司与国家药品不良反应监测中心.药品不良反应报告和监测工作手册［EB/OL］.2021-04-06.http：//www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t2013 0426-5436.htmlhttp://www.cdr-adr.org.cn/xzzx/hyzl/hyzl2013nd/201304/t20130426-5436.html.

中国临床肿瘤学会抗肿瘤药物安全管理专家委员会，中国临床肿瘤学会免疫治疗专家委员会.卡瑞利珠单抗致反应性皮肤毛细血管增生症临床诊治专家共识［J］. 临床肿瘤学杂志，2020，25（9）：840-848.doi：10.3969/j.issn.1009-0460.2020.09.012http://dx.doi.org/10.3969/j.issn.1009-0460.2020.09.012.

Llovet JM，Kelley RK，Villanueva A，et al. Hepatocellular carcinoma［J］. Nat Rev Dis Primers，2021，7（1）：6.doi：10.1038/s41572-020-00240-3http://dx.doi.org/10.1038/s41572-020-00240-3.

郑荣寿，孙可欣，张思维，等.2015年中国恶性肿瘤流行情况分析［J］.中华肿瘤杂志，2019，41（1）：19-28.doi：10.3760/cma.j.issn.0253-3766.2019.01.008http://dx.doi.org/10.3760/cma.j.issn.0253-3766.2019.01.008.

章浙伟，邵国良.重视介入与靶向和免疫联合治疗在中晚期肝细胞癌中的应用前景［J］.实用肿瘤杂志，2022，37（3）：227-231.doi：10.13267/j.cnki.syzlzz.2022.037http://dx.doi.org/10.13267/j.cnki.syzlzz.2022.037.

郭萍，袁志平.三维适形放疗联合TACE治疗中晚期肝癌患者的早期疗效［J］. 肝脏，2020，25（12）： 1269-1271.doi：10.3969/j.issn.1008-1704.2020.12.008http://dx.doi.org/10.3969/j.issn.1008-1704.2020.12.008.

Kubes P，Jenne C. Immune responses in the liver［J］. Annu Rev Immunol，2018，36（1）：247-277.doi：10.1146/annurev-immunol-051116-052415http://dx.doi.org/10.1146/annurev-immunol-051116-052415.

窦留瑞，孙恺.恶性肿瘤免疫治疗出现疾病超进展的研究进展［J］. 肿瘤学杂志，2022，28（3）：172-177.doi：10.11735/j.issn.1671-170X.2022.03.B003http://dx.doi.org/10.11735/j.issn.1671-170X.2022.03.B003.

Markham A，Keam SJ. Camrelizumab： first global approval［J］. Drugs，2019，79：1355-1361.doi：10.1007/s40265-019-01167-0http://dx.doi.org/10.1007/s40265-019-01167-0.

姚红军，胡静，袁灿亮.经导管动脉栓塞化疗联合调强放疗治疗中晚期肝癌的疗效及预后观察［J］. 癌症进展，2022，20（19）： 1996-1998.doi：10.11877/j.issn.1672-1535.2022.20.19.16http://dx.doi.org/10.11877/j.issn.1672-1535.2022.20.19.16.

宋耕，杨震.肝脏广泛转移癌调强放疗10例近期疗效观察［J］.安徽医药，2020，24（7）：1385-1387.doi：10.3969/j.issn.1009-6469.2020.07.029http://dx.doi.org/10.3969/j.issn.1009-6469.2020.07.029.

于士龙，刘东辉，王储，等.TACE联合卡瑞利珠单抗治疗中晚期肝细胞癌［J］.中国介入影像与治疗学，2022，19（7）： 391-395.doi：10.13929/j.issn.1672-8475.2022.07.003http://dx.doi.org/10.13929/j.issn.1672-8475.2022.07.003.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinical efficacy of biofeedback and electrical stimulation on pelvic organ prolapse after laparoscopic uterine suspension

Clinical effect of apical microsurgery combined with guided bone regeneration on refractory apical periodontitis

Efficacy of transjugular intrahepatic portosystemic shunt in the treatment of portal vein thrombosis

Efficacy and safety of percutaneous reduction by bone hook combined with proximal femoral nail anti-rotation internal fixation for femoral intertrochanteric fracture

Effects and safety analysis of patient controlled brachial plexus nerve block analgesia after pediatric upper limb operation

Related Author

YU Xue-mei

CHEN Wei

LIAO Qian

WANG Bin

WANG Jun-yan

MIAO Wei

PIAO Wei-ying

YAO Na

Related Institution

Department of Gynecology， Sichuan Mianyang Hospital

Department of Stomatology，People's Hospital of Inner Mongolia Autonomous Region

Department of Vascular Surgery， First Affiliated Hospital of Army Medical University

Second Department of Arthrology and Osteology，Hengshui Fourth People's Hospital

Department of Anesthesiology,Second People s Hospital of Shenzhen,Guangzhou

⁰